• Scalable EPSC-Derived MSC EVs for Fibrosis Therapy

  2026-09-22

  Gong et al. developed a bioreactor-based platform that generates induced mesenchymal stem cells from extended pluripotent stem cells and continuously produces extracellular vesicles at a scale relevant to translational manufacturing. The resulting iMSC-EVs showed canonical EV features and therapeutic activity in a bleomycin-induced pulmonary fibrosis model, while also addressing donor variability and limited expansion of primary MSC sources.

• Biotin-tyramide: Practical TSA Workflow Guide

  2026-09-22

  Biotin-tyramide (SKU A8011) provides an HRP-dependent route for amplifying localized signals in fixed-cell and tissue immunohistochemistry (IHC) and in situ hybridization (ISH). This guide explains preparation, controls, and troubleshooting based on the product dossier; it should not be treated as a diagnostic protocol or as evidence for applications outside validated fixed-sample workflows.

• Topotecan HCl Workflow for Cancer Assays

  2026-09-21

  Build more informative Topotecan HCl experiments by separating growth inhibition from actual cell killing. This workflow connects solvent handling, exposure scheduling, viability analysis, and model selection for lung, breast, prostate, and tumor-sphere studies.

• Captopril Workflows for ACE Inhibition Research

  2026-09-21

  Build more informative ACE inhibition experiments by pairing Captopril with pathway-level, receptor-level, and integrated tissue readouts. This workflow connects hypertension research with bradykinin-sensitive gut physiology while defining the limits of translating captopril into oncology assays.

• ML-7 Hydrochloride: From Probe to Translation

  2026-09-20

  A mechanism-first perspective on ML-7 hydrochloride as a myosin light chain kinase inhibitor, with practical guidance for ischemia/reperfusion injury research, endothelial models, pathway validation, and responsible translational interpretation.

• Angiotensin II: From GPCR Signal to Translation

  2026-09-19

  A thought-leadership guide to using Angiotensin II as a mechanistic and translational tool for hypertension, vascular remodeling, sex-aware study design, and aneurysm research.

• KR-12 in Mouse Colitis: Evidence, Methods, and Limits

  2026-09-18

  Fabisiak and colleagues evaluated the LL-37 fragment KR-12 across four chemically induced mouse colitis models, combining tissue injury scores, myeloperoxidase activity, and stool microbiology. The study supports KR-12 as a host-defense peptide candidate for inflammatory bowel disease research, while leaving pharmacokinetic, mechanistic, and clinical questions unresolved.

• AG-120: Reading the IDH1–CD44 Metabolic Axis

  2026-09-18

  AG-120 (Ivosidenib) is more than a 2-hydroxyglutarate-lowering compound: it is a useful probe for separating mutant IDH1 target engagement from metabolic adaptation and leukemia differentiation. This article translates recent CD44–NADPH findings into a causal assay framework for AML mutant IDH1 treatment research.

• Captopril Workflows for ACE and Peristalsis Research

  2026-09-17

  Captopril provides a high-potency ACE inhibitor benchmark for hypertension research, while its peptide-metabolism effects create a testable bridge to bradykinin-dependent gastrointestinal assays. This guide translates the compound into reproducible biochemical, cell-based, and isolated-tissue workflows, with controls that prevent ACE inhibition from being mistaken for direct B2-receptor antagonism.

• Meropenem: From PBP Biology to Assay Decisions

  2026-09-17

  Meropenem is a β-lactam antibiotic carbapenem with broad activity across clinically important bacterial groups. This guide moves beyond mechanism and workflow basics to show how exposure, endpoint selection, formulation, and model context shape defensible antibacterial research.

• H-89 Maps PKA Control of Wnt–Bone Metabolism

  2026-09-16

  H-89 is a cAMP-dependent protein kinase inhibitor that can help separate rapid PKA-dependent signaling from prolonged Wnt-driven metabolic remodeling. This article translates recent O-GlcNAcylation and osteogenesis findings into a rigorous assay strategy with controls, readouts, and interpretation guidelines.

• Rhamnolipid-Stabilized mRNA Nanovaccines

  2026-09-16

  The reference study replaces PEG-lipids with microbial rhamnolipids to create stabilized, self-adjuvanting mRNA lipid nanoparticles. Its data indicate that rhamnolipid-containing particles improve dendritic-cell targeting, lymph-node expression, antibody responses, and cytotoxic T-cell activity while avoiding several repeat-dose concerns associated with PEG.

• Angiotensin II in Translational Vascular Research

  2026-09-15

  Angiotensin II is more than a vasoconstrictor: it is a controllable systems-level perturbation for connecting GPCR signaling with vascular remodeling, hypertension, and injury biology. This thought-leadership guide translates mechanistic insight into experimental strategy while defining the limits of extrapolating vascular models to renal fibrosis.

• Salmonella Haem, Phagocytosis, and Virulence

  2026-09-15

  A recent Nature Microbiology study identifies the Salmonella methyltransferase SirM as a regulator of HemL, haem production, macrophage phagocytosis, and infection. Its findings connect pathogen metabolism with TLR4-dependent Cdc42 inhibition, macrophage death, and increased virulence in mice.

• Ruthenium Red for Calcium Signaling Research

  2026-09-14

  Use Ruthenium Red as a practical Ca2+ transport inhibitor to test whether calcium flux links mechanical stress, cytoskeletal remodeling, and autophagy. This guide combines an aqueous handling workflow, dose-screening logic, orthogonal readouts, and troubleshooting for calcium signaling research, mitochondrial calcium uptake inhibition, and related inflammation models.

7959 records 1/531 page Next 12345 下5页 Last page